Sideline Gold on Fe...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$78.80 0.05 | 0.06%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 78.75 |
| 52 Week High | 87.47 |
| 52 Week Low | 38.44 |
| Avg. Daily Vol. (Mil) | 2.55 |
| Beta (3 year) | 0.15 |
| Share Related Items | |
| Mkt Cap (Mil) | 17,435.32 |
| Shares Out (Mil) | 221.40 |
| Float (Mil) | 216.61 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.50 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.98 |
| Total Debt / Equity | 0.99 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 12.31 |
| Price/Book | 23.37 |
| Price/Cash Flow | -42.00 |
| Per Share Data | |
| Earnings | -2.36 |
| Sales | 6.40 |
| Book Value | 3.37 |
| Cash Flow | -1.87 |
| Business Summary | |
|---|---|
| Vertex Pharmaceuticals discovers, develops and commercializes small molecule drugs for the treatment of serious diseases. | |
| General Information | |
| 130 Waverly Street
Cambridge, MA 02139 |
|
| www.vrtx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 2200 | |
| CEO: Dr. Jeffrey M Leiden M.D | |
| Short Interest | |
| Current Month (Mil) | 4.47 |
| Previous Month (Mil) | 7.05 |
| Short Interest Ratio (Days) | 2.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -19.00 |
| Return on Investments | -30.00 |
| Profitability | |
| Gross Margin | 82.80 |
| EBIT Margin | -37.50 |
| Profit Margin | -32.10 |
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- 3 High Risk Hot Stocks To Watch 06.17.13 | 11:06 am
- These Mutated Cystic Fibrosis Cells Are Worth Billions to Vertex Pharma 06.13.13 | 02:06 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 06.11.13 | 05:06 pm
- Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales 06.11.13 | 09:06 am
- 5 Drugs Stocks Dragging The Industry Down 06.10.13 | 01:06 pm
- Biotech's Next Big Thing: Vertex
06.06.13 | 03:06 pm - Remember Vertex? Important Cystic Fibrosis Data On Tap Next Week 06.06.13 | 07:06 am
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Winner 05.30.13 | 05:05 pm
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard 05.16.13 | 05:05 pm
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Market Close Report: NASDAQ Composite index closes at 3,206.06 up 39.70 points - NASDAQ 04.19.13 | 08:04 pm
- Stocks Up, Dow Turns Positive; Leaders Catch An Updraft - Investor's Business Daily 04.19.13 | 12:04 pm
- UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking - Benzinga 04.19.13 | 09:04 am
- Futures Geared For Higher Open; Vertex, Google, Chipotle Rumble - Investor's Business Daily 04.19.13 | 08:04 am
- Stocks Take Another Drubbing, But Google Rises After Hours - Investor's Business Daily 04.18.13 | 05:04 pm
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Market Close Report: NASDAQ Composite index closes at 3,244.37 up 12.28 points - NASDAQ 03.08.13 | 09:03 pm
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
